ABSTRACT Out-of-hospital cardiac arrest (OHCA) is a leading cause of mortality and severe neurological disability. Recent literature suggests that mild therapeutic hypothermia (MTH) can improve survival and neurological outcome in some groups of comatose patients after cardiac arrest but uncertainty exists over the best way to implement this treatment. This review examines the evidence for the efficacy and mode of implementation of MTH after OHCA, particularly in the Emergency Department setting. A literature search was performed and all systematic reviews; human and animal randomised and nonrandomised trials were screened for inclusion. Specific emphasis was placed on MTH being commenced in the prehospital and Emergency Department setting.
INTRODUCTION
Out-of-hospital cardiac arrest (OHCA) is a leading cause of morbidity and mortality in the developed world. Resuscitation is attempted in 66 per 100 000 population across Europe every year. Of those that survive to leave hospital, >50% are left with permanent neurological sequelae. 1 The first clinical intervention in the postresuscitation phase of OHCA shown to decrease mortality and improve neurological outcome is mild therapeutic hypothermia (MTH). 2 3 MTH was used in patients with OHCA as early as 1950, but cooling was largely abandoned due to complications. The concept of preserving the brain in the field, protecting it from hypoxia until the patient could be transported to hospital for spontaneous circulation to be restored or placed on cardiopulmonary bypass, was first suggested by Peter Safar in 1984. 4 5 In the 1990s, a number of encouraging animal studies showed benefit, and several pilot human studies were conducted. 6 7 In 2002, two randomised trials demonstrated the benefit of cooling survivors of witnessed OHCA who had ventricular fibrillation (VF) as the presenting rhythm. 2 3 This led to the International Liaison Committee on Resuscitation, the American Heart Association and the European Resuscitation Council recommending MTH in the management of unconscious patients following OHCA. 8 9 Despite these recommendations, the use of MTH is not yet routine. 10 Since 2002, further trials have explored the use of MTH for non-VF OHCA, traumatic cardiac arrests and in paediatric patients.
The optimum initiation, method and duration of cooling are unclear. 11 Animal research suggests that cooling early after return of spontaneous circulation (ROSC) is associated with improved neurological outcome, 12 13 but human studies show that delayed cooling also yields favourable results. 3 12 14 Both invasive and non-invasive cooling methods have been developed, and whole-body and brainonly cooling methods have been trialled. The majority of cooling techniques have been trialled in critical care settings with few methods specifically evaluated in the Emergency Department (ED). 15 While MTH initiated in the ED may reduce the time taken to reach target temperature, prehospital cooling poses logistical and technical challenges. Patients arriving at hospital after OHCA may require in-hospital transfer for imaging or cardiac intervention prior to ICU (intensive care unit) admission. Cooling techniques intended for early deployment must therefore combine efficacy with ease of use.
While some ambulance services and EDs have adopted MTH as a routine treatment for patients after OHCA, it is unclear whether the available evidence supports this practice.
This paper aims to review and discuss key elements of the published literature on using MTH in the emergency setting and is not intended to provide a definite statement in the form of a systematic review.
We reviewed the published literature to answer the following: 
METHODS
A literature review was performed by a single investigator. All short-listed studies were assessed by the other two authors for quality and to ensure the inclusion criteria were met. Search terms included 'therapeutic hypothermia', 'hypothermia', 'cardiac arrest', 'heart arrest', 'out-of-hospital cardiac arrest' and 'cardiopulmonary resuscitation'. Outcome parameters included in-hospital mortality, 6-month mortality and favourable neurological outcome (defined as independent living) within 6 months. Inclusion criteria were studies commencing cooling early post-ROSC. For human studies we included those commencing cooling prehospital or in the ED. For animal studies we included cooling before, during or immediately after cardiac arrest. Specific exclusion criteria included non-cardiac arrest conditionsdfor example, myocardial infarction, cerebrovascular accident and traumatic brain injury. In contrast to previous published systematic reviews, 16 17 this review specifically examines MTH use in the prehospital and ED setting. We found the number of randomised controlled trials (RCTs) on the use of MTH after OHCA to be small; therefore, all RCTs were screened for inclusion, regardless of the timing of initiation of cooling.
We included literature searches from Ovid Medline 1950e2009, the Cochrane Library, EMBASE 1988e2009, Google scholar and citation tracking. The search sought to identify studies that evaluated the use of MTH following OHCA using the search criteria above. Finally, a Web of Science citation search was performed on all included studies. Reference lists of all available primary studies and review articles were obtained to identify potentially relevant citations. Previously published systematic review articles were sought, looking for particular relevance to using MTH in the prehospital and ED setting. After a generalised search, limits were applied for 'trials'.
Human trials were assessed using the Jadad system 18 to assess internal validity. This allows a measure of comparison of quality between trials.
RESULTS
One thousand and sixty-two papers were screened for inclusion. These were subdivided into animal studies, non-randomised studies, randomised trials and systematic reviews. Two systematic reviews and five randomised clinical trials were identified. Five animal trials comparing timing of cooling initiation were included.
Animal studies
The first animal studies using hypothermia after cardiac arrest were reported in the 1950s. In the early 1960s, Peter Safar observed that dogs that were mildly hypothermic at the initiation of experimental cardiac arrest had a better neurological outcome than dogs that were normothermic. 19 A summary of selected animal studies is shown in table 1. These particularly relate to early cooling and the potential effect this may have on outcome.
The discovery of the neuroprotective effects of mild to moderate hypothermia led to the investigation of resuscitative hypothermia in several animal models. Dogs treated with immediate mild (348C) or moderate (308C) hypothermia showed improved functional and histological outcome. Dogs treated with deep hypothermia (158C), however, showed no improvement in neurological function and had more severe cerebral histological changes compared with mild or moderate hypothermia groups. 13 23 In the same model, delaying the onset of cooling until 15 min postreperfusion was not associated with the same improvement in functional outcome but did improve histological damage. MTH was not associated with any significant side effects in these studies.
More recently a trend towards better outcomes after earlier initiation of therapeutic hypothermia (<15 min post-ROSC) has been demonstrated. 20 22 Kuboyama and colleagues demonstrated that survival without neurological deficit can still be achieved after 40 min of VF cardiac arrest in dogs when intra-arrest hypothermia is instigated using cold intravascular fluids. However, a delay in cooling after the induction of VF was associated with an increased mortality and poorer neurological outcomes. 20 Nozari showed that early intra-arrest cooling in dogs with 60 min of VF resulted in a favourable neurological outcome. 21 However, when cooling was delayed until 20 min after onset of VF, seven of eight dogs did not survive. Abella and colleagues showed that mice cooled 20 min after cardiac arrest showed a higher mortality than mice cooled just prior to resuscitation from an 8 min period of cardiac arrest. 22 Zhao demonstrated in a randomised, controlled, murine model that delaying resuscitation to institute therapeutic hypothermia still resulted in a favourable neurological outcome. 12 The animal studies reviewed suggest that cooling should commence with a minimum of delay after cardiac arrest and should continue for at least 24 h to confer lasting neuroprotection.
Non-randomised trials
The first reported human studies using therapeutic hypothermia were reported in 1958. 24 Since then >20 non-randomised studies have been published. The target temperature has consistently been 32e348C using a variety of cooling techniques. Reported favourable neurological outcome rates vary from 25% to 68%. A summary of non-randomised trials is shown in table 2.
In 1997, Bernard and colleagues conducted a pilot study comparing patients treated with MTH, induced by the application of ice packs, with normothermic controls. They demonstrated improved outcome in the treatment group, without significant complications. 6 Yanagawa cooled 13 patients who had survived initial resuscitation. 7 Cooling to 338C commenced on arrival at the ED (time to target temperature of 5.5 h post-ROSC) and was maintained for 48 h before slowly rewarming at 18C per day.
Further studies adopted progressively more sophisticated means of inducing therapeutic hypothermia. A study using cold air surface cooling in the ED by Zeiner and colleagues was successful in lowering core body temperature. 25 Despite nonsignificant results, these studies supported the evidence that MTH was a safe clinical intervention and could improve outcome after OHCA.
Cooling modalities are summarised in table 3. Methods of initiating prehospital cooling have been investigated, with cold fluids and ice packs being the modalities of choice. 28 29 Other methods of cooling, including body surface cooling with ice and cold blankets, helmet devices, endovascular cooling catheters, haemofiltration and coronary bypass, have been studied. None of these combines efficacy with ease of use. A key finding is that infusion of up to 2 litres of cold (48C) intravenous fluid (0.9% saline or Ringer's lactate) in the immediate post-ROSC phase is an effective and safe method of cooling and is not associated with significant complications or cardiovascular instability. Whatever the cooling technique employed the degree of hypothermia induced is important, and Merchant and colleagues have demonstrated that overcooling is a significant risk and careful core body temperature monitoring is mandatory. 30 The risks of overcooling include infection, coagulopathy and cardiac arrhythmias.
Randomised trials
Five randomised clinical trials of therapeutic hypothermia post-IHCA have been published. 2 3 32e34 These are summarised in table 4. The first clinical trial of therapeutic hypothermia, published in 2001, 32 enrolled 30 patients following OHCA with asystole or pulseless electrical activity (PEA) as the initial cardiac rhythm. Sixteen patients were cooled to 348C for a maximum of 4 h with a helmet cooling device and then allowed to rewarm passively. Two of the patients treated with MTH survived with a favourable neurological outcome compared with no patients in the normothermia group.
In 2002, two prospective, RCTs of MTH in the postresuscitation management of witnessed OHCA were published. Both of these studies recruited a highly selective cohort of patients, with 92% of patients initially assessed for eligibility excluded. Recruitment criteria for both trials were similar and included ROSC in patients who remained intubated and ventilated after OHCA due to VF of presumed cardiac aetiology.
The European trial cooled 136 patients to a core temperature of 32e348C using a mattress cover that delivered cold air. The aim was to reach target temperature within 4 h of ROSC, maintain it for 24 h and then allow passive rewarming to occur. The study showed the number needed to treat (NNT)¼6 (RR 1.40, 95% CI 1.08 to 1.81) for a favourable neurological outcome when MTH was used. The overall mortality at 6 months was reduced from 55% in the normothermia group to 41% in the MTH group, NNT¼7 (RR 40.74, 95% CI 0.58 to 0.95).
In the Australian study cooling was initiated prehospital by applying ice packs to the head and torso. The target temperature (338C) was maintained for 12 h posthospital admission before patients were actively rewarmed after 18 h. Forty-three patients were cooled; 21 (49%) had a favourable neurological outcome of living at home or within a rehabilitation facility (RR 1.85, 95% CI 0.97 to 3.49, NNT¼4). Mortality was reduced from 68% to 51% in the hypothermia group (RR 0.76, 95% CI 0.52 to 1.10, NNT¼6). These findings led to the European Resuscitation Council, in association with the International Liaison Committee on Resuscitation and the American Heart Association, recommending MTH as standard treatment for OHCA victims that achieve ROSC following a VF arrest. 8 A randomised trial 33 of inducing MTH by isovolumic haemofiltration in patients after OHCA showed an increased survival benefit, but it was unclear whether this was conferred by the hypothermic or filtration processes. This technique is not suitable for use in the emergency and prehospital environment.
A recent clinical pilot study explored the benefit of cooling patients immediately after OHCA using intravenous cold saline administered by paramedics in the field. 34 An infusion of 500e2000 ml of 0.9% saline at 48C was administered. Subsequent in-hospital cooling was at the discretion of the attending physician. Sixty-three patients were treated with prehospital hypothermia. Only 78% of patients in the hypothermia group received further cooling. Prehospital cooling led to a significantly lower temperature on arrival at hospital (34.78C vs 35.78C, p<0.0001). There was no significant difference in survival to hospital discharge in the hypothermia versus normothermia groups (33% vs 29%, p¼0.70). Subgroup analysis of patients with VF as the initial cardiac rhythm showed a trend towards increased survival to hospital discharge but there was a trend towards increased mortality in the cooling group where the initial cardiac rhythm was PEA or asystole.
Systematic reviews
Two systematic reviews matched our inclusion criteria. Cheung et al reviewed the combined data from four RCTs in 2006, representing 436 patients. 17 Inclusion criteria were adults with primary OHCA who remained comatose after ROSC. The clinical trials ranged from score 1 to 3 on the Jadad scale and AeC on the Cochrane grade score. The combined data showed that MTH decreased in-hospital mortality (RR 0.75, 95% CI 0.62 to 0.84). The review concluded that MTH had an NNT of 5 to improve neurological outcome and an NNT of 7 to save a life. However, the review failed to draw conclusions on the optimum cooling method, rate or duration of cooling. No evidence of treatment-limiting side effects was reported.
A meta-analysis 16 of three trials has shown that patients treated with hypothermia show an increased rate of survival with favourable neurological outcome (RR 1.68, 95% CI 1.29 to 2.07). The calculated 95% CI for the NNT to result in a patient being discharged from hospital with a favourable neurological outcome ranged from 4 to 13.
DISCUSSION
There is strong evidence to support the use of MTH in comatose patients after OHCA whose initial cardiac rhythm was VF. The evidence supporting MTH use in other presenting cardiac rhythms is less clear and further studies are required. Despite animal studies demonstrating the benefit of immediate cooling, either during cardiopulmonary resuscitation (CPR) or immediately post-ROSC, 12 20 22 the existing evidence from human studies is less clear.
14 Practically, initiating cooling in the prehospital environment is challenging; however, several studies have shown that initiating cooling in the ED is feasible and effective. 27 28 31 The different cooling modalities are shown in table 3. The use of ice packs is a simple, but relatively slow, means of cooling. A bolus of cold intravenous fluids combines efficacy with ease of use and is not associated with significant unwanted side effects. This is probably the cooling method of choice for the ED. Intravenous fluids can be stored in a refrigerator within the ED and administered to patients following OHCA shortly after arrival in hospital. Initiating cooling in the ED is likely to shorten the time to target temperature, particularly if the patient requires coronary intervention or radiological imaging prior to ICU admission. Cooling with cold intravenous fluids can continue during transfer or during clinical procedures.
The three phases of therapeutic hypothermia are induction, maintenance and rewarming. For all phases, accurate core body temperature measurement is essential to ensure accurate cooling and prevent overcooling. For rapid induction, oesophageal or central venous temperature should be measured, as probes in the bladder or rectum do not reflect core body temperature accurately. 35 Overcooling is common. 30 After induction, therapeutic hypothermia can be maintained on the ICU with body surface cooling techniques with accurate feedback mechanisms, or invasive, endovascular cooling techniques. In order to prevent shivering, paralysis and sedation are required. The optimum length of time for which MTH should be maintained remains unknown, 11 36 but previous studies have used maintenance periods of 12e48 h. 2 3 The optimum means, whether active or passive, and rate of warming are unknown, and further research is required to improve the induction, maintenance and rewarming phases.
Despite strong evidence suggesting benefit, uptake of therapeutic hypothermia in routine clinical practice has been slow. 10 37 Lack of awareness, fear of a novel treatment and unknown side effects, as well as lack of equipment, have been cited as barriers to MTH implementation. 38 
CONCLUSION
The use of MTH in patients who remain comatose after OHCA improves survival and neurological outcome. The optimal time of initiation, cooling method and target temperature have yet to be established. Cooling is feasible within the ED, and cold intravenous crystalloid infusion is effective, simple and safe. Wider awareness among ED medical staff may increase the early use of therapeutic hypothermia in patients after OHCA.
